Elekta VMAT solution receives FDA 510(k) clearances

137

Elekta has received FDA 510(k) clearances for its groundbreaking Elekta VMAT solution, allowing US cancer specialists to both plan and deliver radiation using a technique which has the potential to revolutionize the practice of radiation oncology.

Elekta has received FDA 510(k) clearances for its groundbreaking Elekta VMAT solution, allowing US cancer specialists to both plan and deliver radiation using a technique which has the potential to revolutionize the practice of radiation oncology.

From the doctor's view, the reduction in treatment time makes it much easier to accurately target the tumor and the improved dose sparing offers new options to either increase dose to tumor or reduce side effects and therefore potentially improve outcomes. From the patient's perspective Elekta Volumentric intensty Modulated Arc Therapy combines a significant reduction in treatment time with optimal avoidance of radiation dose to healthy tissues surrounding the tumor.

Elekta is uniquely positioned to introduce the VMAT technique by virtue of Elekta Synergy ®, the only fully digital linear accelerator with integrated high-resolution 3D X-ray Volume Imaging (XVI). With daily pre-treatment imaging scans, clinicians who implement Elekta VMAT will be able to maximize accuracy and shrink treatment margins, while minimizing the possibility of damage to surrounding healthy tissue.

Tomas Puusepp, President & CEO of Elekta said, Over ten years of research in collaboration with members of the Elekta IMRT Consortium has lead to this unique series of innovations.  Having the worlds only fully digital accelerator is a key element in making this level of automation and control complexity possible in a way that allows clinicians to deliver advanced treatments with a single push of a button.